Affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10: strategy for selection of an optimal candidate

by Ellen C. Border, Joseph P. Sanderson, Thomas Weissensteiner, Andrew B. Gerry, Nicholas J. Pumphrey
Published 2019-02-01

Innate-like control of human iNKT cell autoreactivity via the hypervariable CDR3beta loop.

by Gediminas Matulis, Joseph P Sanderson, Nikolai M Lissin, Maria B Asparuhova, Gopal R Bommineni, Daniel Schümperli, Richard R Schmidt, Peter M Villiger, Bent K Jakobsen, Stephan D Gadola
Published 2010-06-01

Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy

by Joseph P Sanderson, Darragh J Crowley, Guy E Wiedermann, Laura L Quinn, Katherine L Crossland, Helen M Tunbridge, Terri V Cornforth, Christopher S Barnes, Tina Ahmed, Karen Howe, Manoj Saini, Rachel J Abbott, Victoria E Anderson, Barbara Tavano, Miguel Maroto, Andrew B Gerry
Published 2020-01-01

An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules.

by Jane Harper, Katherine J Adams, Giovanna Bossi, Debbie E Wright, Andrea R Stacey, Nicole Bedke, Ruth Martinez-Hague, Dan Blat, Laure Humbert, Hazel Buchanan, Gabrielle S Le Provost, Zoe Donnellan, Ricardo J Carreira, Samantha J Paston, Luise U Weigand, Martina Canestraro, Joseph P Sanderson, Sophie Botta Gordon-Smith, Kate L Lowe, Karolina A Rygiel, Alex S Powlesland, Annelise Vuidepot, Namir J Hassan, Brian J Cameron, Bent K Jakobsen, Joseph Dukes
Published 2018-01-01